Trial Profile
An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
- Focus Adverse reactions
- Sponsors Amgen
- 15 Jun 2023 Results of five year interim analysis assessing effectiveness and safety data of blinatumomab in these pts presented at the 28th Congress of the European Haematology Association
- 23 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2021 Planned End Date changed from 22 Mar 2024 to 21 Mar 2024.